| Outcome Measures: |
Primary: Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough, Percent inhibition of DPP-4 activity at 24 hours after the Day 5 morning dose (i.e., at trough) was determined by analysis of blood samples collected from the study participants., 24 hours following the final morning dose on Day 5 | Secondary: Pharmacokinetic Analysis: Area Under the Curve 0-24 Hours (AUC 0-24hr), AUC 0-24hr is the area under the plasma drug concentration-time curve calculated for the 24 hour interval after the Day 5 morning dose., Predose (0 Hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20 and 24 hours after the morning dose on Day 5|Pharmacokinetic Analysis: Area Under the Curve 0-12 Hours (AUC 0-12hr) for Vildagliptin 50 mg BID, AUC 0-12hr is the area under the plasma drug concentration-time curve calculated for the 12 hour interval after the Day 5 morning dose for the vildagliptin 50 mg BID dose only., Predose (0 hours) and 0.5, 1, 2, 4, 8 and 12 hours after the morning dose on Day 5|Pharmacokinetic Analysis: Peak Plasma Drug Concentration (Cmax), Measurement of the peak plasma drug concentration following the Day 5 morning dose., Predose (0 hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20, 24, 36, 48 and 96 hours after the morning dose on Day 5|Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax), Measurement of the time to the peak plasma drug concentration following the Day 5 morning dose., Predose (0 hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20, 24, 36, 48 and 96 hours after the morning dose on Day 5
|
